Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dabrafenib + trametinib + spartalizumab
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination of **dabrafenib** (a BRAF inhibitor), **trametinib** (a MEK inhibitor), and **spartalizumab (PDR001)** (a monoclonal antibody targeting PD-1 immune checkpoint). This regimen is used in investigational clinical trials primarily for BRAF V600-mutant cancers, especially melanoma and metastatic colorectal cancer. Dabrafenib inhibits BRAF V600-mutant kinase activity, trametinib inhibits MEK1/2 downstream in the MAPK pathway, and spartalizumab blocks the PD-1 receptor, enhancing anti-tumor immune response[1][2][3][4][5][9][10].
- Other names
- dabrafenib + trametinib + PDR001
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)BRAF V600E
Beyond the preview
Go deeper on dabrafenib + trametinib + spartalizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dabrafenib + trametinib + spartalizumab.